Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies
© The Author(s). 2017
Received: 10 March 2016
Accepted: 9 December 2016
Published: 17 January 2017
Anti-tuberculosis drug resistance is a major public health problem that threatens the progress made in tuberculosis care and control worldwide. Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) is a key issue that cannot be ignored. There is a paucity of evidence that assessed studies on the treatment of MDR-TB, which focus on the effectiveness of the directly observed treatment, short-course (DOTS)-Plus program. Therefore, it is crucial to assess and summarize the overall treatment outcomes for MDR-TB patients enrolled in the DOTS-Plus program in recent years. The purpose of this study was to thus assess and summarize the available evidence for MDR-TB treatment outcomes under DOTS-Plus.
A systematic review and meta-analysis of published literature was conducted. Original studies were identified using the databases MEDLINE®/PubMed®, Hinari, and Google Scholar. Heterogeneity across studies was assessed using the Cochran’s Q test and I2 statistic. Pooled estimates of treatment outcomes were computed using the random effect model.
Based on the 14 observational studies included in the meta-analysis, it was determined that 5 047 patients reported treatment outcomes. Of these, the pooled prevalence, 63.5% (95% CI: 58.4–68.5%) successfully completed full treatment (cured or treatment completed) with a pooled cure rate of 55.6%, whereas 12.6% (95% CI: 9.0–16.2%) of the patients died, 14.2% (95% CI: 11.6–16.8%) defaulted from therapy, and 7.6% (95% CI: 5.6–9.7%) failed therapy. Overall 35.4% (95% CI: 30–40.8%) of patients had unsuccessful treatment outcomes. An unsatisfactorily high percentage 43% (95% CI: 32–54%) of unsuccessful treatment outcomes was observed among patients who were enrolled in standardized treatment regimens.
This study revealed that patients with MDR-TB exhibited a very low treatment success rate compared to the World Health Organization 2015 target of at least 75 to 90%. The high default rate observed by conducting this literature review could possibly explain the spread of the MDR-TB strain in various populations. A better treatment success rate was observed among patients in individualized treatment regimens than in standardized ones. Conducting further individual-based meta-analysis is recommended to identify potential factors for defaulting treatment using large-scale and multi-center studies.
KeywordsTuberculosis Multidrug resistance DOTS-Plus Multidrug-resistant tuberculosis Treatment outcomes
Please see Additional file 1 for translations of the abstract into the six official working languages of the United Nations.
Anti-tuberculosis (TB) drug resistance is a major public health problem, which threatens the progress made in the control of TB worldwide. Drug resistance occurs due to the improper use of antibiotics during chemotherapy of drug-susceptible TB patients. This incorrect use is a result of a number of factors such as administration of inappropriate treatment regimens and failure to ensure that patients complete the whole course of treatment .
Globally, 5% of TB cases were estimated to have developed multidrug-resistant TB (MDR-TB) (defined as resistance to at least isoniazid and rifampin) in 2013 (3.5% new and 20.5% previously treated TB cases). Likewise, drug resistance surveillance data have shown that an estimated 480 000 people developed MDR-TB worldwide in 2013, and out of this, 210 000 people died . In 1999, the Green Light Committee (GLC), a partner of the World Health Organization (WHO), launched the “directly observed treatment, short-course (DOTS)-Plus for MDR-TB” programs for patients with MDR-TB. The program emphasizes the usage of appropriate second-line drugs (SLDs) in low- and middle-income settings. By the end of 2006, more than 50 DOTS-Plus pilot programs had been launched by GLC, and more than 20 000 patients with MDR-TB were under treatment .
The DOTS-Plus program, which stresses the combination of first- and second-line drugs to treat MDR-TB, is becoming increasingly important for MDR-TB control globally. The core components are comprehensive to ensure that all essential elements of the DOTS-Plus strategy are included. They are the following: sustained political and administrative commitment; diagnosis of MDR-TB through quality-assured culture and drug susceptibility testing; appropriate treatment strategies that utilize SLDs under proper management conditions; and uninterrupted supply of quality-assured anti-TB drugs .
Treatment of MDR-TB involves the use of SLDs, which are more complex, toxic, costly, and less effective, are associated with a greater incidence of adverse reactions [4, 5], and require longer treatment duration than first-line drugs.
The WHO aimed to achieve the target of at least 75 to 90% treatment success rate for TB patients by 2015 , but current studies on MDR-TB treatment reveal a huge gap in reaching this target. According to a WHO 2014 report, only 48% of patients with MDR-TB in 2011 were successfully treated, 16% died, 24% did not have their treatment outcomes documented or interrupted treatment, and 12% were not cured despite receiving treatment . Hence, unsuccessful treatment of MDR-TB is a key problem that cannot be neglected. There is a paucity of evidence that assessed studies on the treatment of MDR-TB, which focus on the effectiveness of the directly observed treatment, short-course (DOTS)-Plus program . Therefore, it is very important to review and summarize the overall treatment outcomes for MDR-TB under DOTS-Plus in recent years. The aim of this study was to assess and summarize the available evidence on MDR-TB treatment outcomes under DOTS-Plus.
Study design and data sources
A systematic review and meta-analysis of published observational studies was conducted. Original studies providing information on the treatment outcomes of patients with MDR-TB under DOTS-Plus were identified through a computerized search using the databases MEDLINE®/PubMed®, Google Scholar, Embase®, and Health InterNetwork Access to Research Initiative (Hinari). A detailed search strategy was implemented and reference lists were cross-checked. A combination of keywords and phrases, namely “tuberculosis”, “drug resistance”, “multidrug resistance”, “DOTS-Plus”, “MDR-TB”, and “treatment outcomes” were used to search for articles in the databases. The International Journal of Tuberculosis and Lung Disease was selected as the key journal for hand searching. At the same time, a hand search was also done for cross-reference lists from identified original articles and reviews for other relevant articles. The literature search, review, and data abstraction was performed from February 1 to August 30, 2015.
Observational studies obtained from the literature search were checked by title and citation. References from the selected studies were also assessed to ensure that no relevant studies were omitted. Studies were required to meet the following inclusion criteria: 1) involving culture-confirmed MDR-TB; 2) treatment outcome definitions specified by mycobacterial culture endpoints (e.g., “cured” defined as at least five consecutive negative cultures during the last 12 months of treatment); 3) clearly defined treatment protocols including SLDs; and 4) outcomes reported according to the WHO classification of success (including cure or treatment completion), failure, default (treatment interruption), and death . Reports on original studies, unpublished master’s theses, and PhD dissertations written in English were also considered.
Operationalization of outcome measures
Cured: defined as a patient who had completed treatment according to program protocol and who has been consistently culture-negative (with at least five results) for the final 12 months of treatment.
Treatment completed: defined as a patient who had completed treatment according to program protocols, but does not meet the definition of “cured” because of a lack of bacteriological results.
Died: defined as a patient who died for any reason during the course of TB treatment.
Treatment failed: if two or more of the five cultures recorded in the final 12 months of treatment were positive, or if any one of the final three cultures was positive.
Lost to follow-up: defined as a patient whose TB treatment was interrupted for two or more consecutive months for any reason.
Transferred out: defined as a patient who had been transferred to another reporting and recording unit, and for whom the treatment outcome was unknown.
For the purposes of this review, those cured or who completed their treatment was categorized as successful treatment outcomes, whereas the others were categorized as unsuccessful treatment outcomes.
Assessment of methodological quality
Studies were assessed for quality and the high-quality studies were then analyzed. The studies were considered high quality if they reported outcomes on at least 10 patients; involved culture-confirmed MDR-TB; were prospective cohort (PC), retrospective cohort (RC), or case control in design; reported an average treatment duration of ≥18 months; reported basic demographic data; and reported that less than 20% of patients were lost to follow-up. When study populations overlapped, we included the more recent and larger study population in the analysis.
Two reviewers (YM and KTK) performed data abstraction independently using a pretested standard abstraction form. The selected studies were reviewed to extract the following data: title; author(s); year of publication; study design; study site; sample size; data collection procedures; type of MDR-TB (primary, acquired); HIV status; duration of MDR-TB treatment; MDR-TB regimen (individualized treatment versus standardized treatment); response rates; and MDR-TB treatment outcomes. When there was a disagreement in data abstraction between the two investigators, it was resolved through discussion and consensus.
Epi Data version 3.1 (EpiData Data Entry, Data Management and basic Statistical Analysis System. Odense Denmark, EpiData Association) and Stata version 11.0 (Stata Corp., College Station, Texas, USA) were used for data entry and analysis, respectively. The detail description of the original studies was presented in a table and forest plot. The pooled estimate of MDR-TB treatment was determined using the Dersimonian-Laird for random effects meta-analysis (random effects model), and was measured as proportions of treatment outcomes with 95% confidence intervals (CIs).
Subgroup analyses was performed by type of treatment regimen.
Statistical heterogeneity and exploration of publication bias
The Begg’s rank correlation test and Egger weighted regression test were used to statistically assess publication bias, and p < 0.05 was considered as indicative of statistically significant publication bias.
Statistical heterogeneity between studies was evaluated using the Cochran’s Q test, which shows the amount between study heterogeneity and I2 statistic. The I2 statistic is a measure of the percentage of variability (inconsistency) between studies that happened due to by chance as conflicted to the actual difference between study populations. Therefore, the presence of statistical heterogeneity was tested using Cochran’s Q test (P < 0.10 indicative of statistically significant heterogeneity) and I2 test (values of 25, 50 and 75% were considered to represent low, medium, and high heterogeneity, respectively) [9–11].
We identified a total of 203 original articles, from the initial computer-based search, in the databases PubMed®, Hinari, and Google Scholar. Nine additional articles were identified through hand searching. Of these, 149 studies were excluded: 71 were duplicated studies, 19 did not examine patients with MDR-TB, 24 were not targeting MDR-TB treatment outcomes, and 35 did not describe treatment under DOTS-Plus. Therefore, 63 full-text studies were eligible for in-depth analysis. Here again, after a careful evaluation, two were excluded because of language restrictions (not English), 42 were excluded because they failed to report on standard outcomes, and five were excluded as they involved sample sizes of less than 10 patients with MDR-TB. Finally, the 14 remaining articles were used for the meta-analysis, including a total study population of 5047 patients from eight high-burden MDR-TB countries, namely Peru, Latvia, Estonia, Russia, the Philippines, India, South Africa, and Uzbekistan (including Karakalpakstan). Figure 1 shows how the studies were selected.
Characteristics of studies included in the review
Summary of the 14 observational studies assessing the treatment outcomes for patients with MDR-TB under DOTS-Plus that were included in the meta-analysis (n = 14)
Kurbatova et al. 
Singla et al. 
Keshavjee et al. 
Riekstina et al. 
Cox et al. 
Shin et al. 
Holtz et al. 
12–18 months after conversion
Leimane et al. 
12–18 months after conversion
Tupasi et al. 
Arora et al. 
Mitnick et al. 
15 months after conversion
Jain et al. 
Farley et al. 
12–18 months after conversion
Van Deun et al. 
The lowest cure rate (21%) was reported in a study conducted in South Africa and the highest cure rate (77%) was reported in a study conducted in Russia.
To determine the pooled treatment success rate of patients with MDR-TB enrolled in DOTS-Plus programs and thus receiving SLDs, we analyzed data from 14 studies in eight countries, which reported on treatment outcomes for a total of 5 047 patients. The results of this meta-analysis revealed that high proportions of patients had poor treatment outcomes. The subgroup analysis further showed that treatment success rate was higher in studies that reported on individualized treatment regimens.
Standardized treatment ensures that all patients with MDR-TB receive the same treatment regimens involving a common drug susceptibility test (DST) of the prevalent MDR-TB strains. Individualized treatment, on the other hand, highlights the provision of treatment based on a previous history of anti-TB treatment, while also taking into account DST results from the most recent isolate obtained from the patient [12, 13].
Empirically, an individualized treatment strategy for MDR-TB requires ready access to reliable laboratory facilities and to healthcare providers who are trained to prescribe the regimens and interpret the results . It is likely that individualized treatment may be very difficult to administer in resource-limited settings, as compared to standardized treatment. However, individualized treatment improves selection of effective drugs that can result in high treatment success for patients and prevents the acquirement of a further resistance strain.
Our study, unlike previous reviews [7, 15], solely focused on MDR-TB treatment outcomes under the recently implemented DOTS-Plus program. Previous systematic reviews and meta-analyses of studies on MDR-TB included treatment outcomes under all programs (including DOTS, and DOTS-Plus). Our meta-analysis showed that the treatment success rate was 63.48%. This finding is consistent with two previous reviews. According to Orenstein et al.  and Johnston et al.  meta-analysis studies, the overall pooled prevalence of MDR-TB treatment success estimates were 62% (95% CI, 58–67%) and 62% (95% CI, 57–67%), respectively.
The WHO aimed to achieve at least 75 to 90% treatment success rate for TB patients by 2015 , and to administer better treatment for MDR-TB patients. To do this, in 1992, the WHO launched the “DOTS-Plus for MDR-TB” programs aimed at MDR-TB patients, stressing the appropriate usage of SLDs in low- and middle-income settings . But the current pooled analysis showed that there are huge gaps in achieving this target and that the DOTS-Plus strategy does not result in significant changes in MDR-TB treatment success rates, this implicates that more stringent activities and mobilization of resources for the treatment and control of MDR-TB is required than ever made.
The current review and meta-analysis of 14 observational studies revealed high rates of default (14.2%) and death (12.6%). Similar findings were reported in previous systematic review studies: Johnston et al.  reported a 13% (9–17%) default rate and a 11% (9–13%) death rate, and Orenstein et al.  found that the default and death rates were 12% (8–16) and 11% (7–15), respectively. Even though the treatment success rate was encouraging, the current review revealed that the DOTS-Plus treatment strategy cannot achieve the WHO treatment success target .
Limitations of the study
Our review had several limitations. We relied exclusively on observational data for treatment outcomes. This may underestimate pooled treatment outcomes. Secondly, this study only searched for studies published in English, which may have resulted in information being missed about the DOTS-Plus program for MDR-TB reported in other languages. Presence of high heterogeneity across studies is another limitation of this review.
This meta-analysis revealed that a low MDR-TB treatment success rate among patients, which is far from the WHO target to be achieved by 2015. A significant proportion of patients defaulted from treatment (14%), or died (12.6%), which is a serious public health concern that needs to be addressed urgently. The high default rate could possibly explain the spread of the MDR-TB strain in various populations. Better treatment success rates were observed among patients in individualized treatment regimens rather than in standardized ones. Further individual-based meta-analysis is recommended to identify potential factors for defaulting treatment using large-scale and multi-center studies.
Directly observed treatment, short-course-Plus
Drug susceptibility test
Green Light Committee
Health InterNetwork Access to Research Initiative
World Health Organization
The authors would like to thank Dr. Bassey Ebenso for his great help in proofreading and editing the language of the entire manuscript.
The authors declare that they did not receive funding for this research from any source.
Availability of data and materials
All the data and materials are readily available and freely available to any researcher wishing to use them.
KTK contributed to the design of the study; collected, entered, analyzed, and interpreted the data; and prepared the paper. YM contributed to the conception and design of the study, data analysis, and interpretation, and drafted the paper. PM contributed to the interpretation and reviewing of the results. SB helped to interpret the results, and in drafting and critically reviewing the paper. All authors read and approved the final paper.
The authors declare that they have no competing interests.
Ethics approval and consent to participate
The study is based on a systematic review of published data and thus did not require ethical clearance.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- World Health Organization update on multi-drug resistance tuberculosis, October 2014. http://www.who.int/tb/challenges/mdr/. Accessed 12 Dec 2015.
- Nathanson E, Lambregts-van Weezenbeek C, Rich ML, Gupta R, Bayona J, Blöndal K, et al. Multidrug-resistant tuberculosis management in resource-limited settings. Emerg Infect Dis. 2006;12(9):1389.View ArticlePubMedPubMed CentralGoogle Scholar
- Central TB Division, Directorate General of Health Services, Ministry of Health & Family Welfare. DOTS-Plus Guidelines 2006. Nirman Bhavan, New Delhi: Revised National Tuberculosis Control Programme; pp. 1–46.
- Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis. 2004;8:1382–4.PubMedGoogle Scholar
- Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line anti-tuberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167:1472–7.View ArticlePubMedGoogle Scholar
- World Health Organization. The global plan to stop TB 2011–2015: transforming the fight towards elimination of tuberculosis – reprinted with changes, 2011. WHO; 2011. Available at www.who.int/iris/bitstream/10665/44437/1/9789241500340_eng.pdf.
- Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet. 2009;9:153–61.View ArticlePubMedGoogle Scholar
- WHO. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. Geneva: WHO; 2008.Google Scholar
- Tania B, Meca JS, Martinez FM. Assessing heterogeneity in meta-analysis. Q statistic or I2 index. Psychol Methods. 2006;11(2):193–206.View ArticleGoogle Scholar
- Borenstein M, Hedges L, Higgins J, Rothstein H. Introduction to Meta-Analysis. 1st ed. Chichester: John Wiley & Sons, Ltd The Atrium, Southern Gate; 2009
- Higgins JP, Thopson SG, Deeks JJ, Altman DG. Measuring inconsistency in Meta-Analysis. BMJ. 2003;327(7414):33–54.View ArticleGoogle Scholar
- Laniado-Laborín R. Multidrug-resistant tuberculosis: standardized or individualized treatment? The question has already been answered. Expert Rev Respir Med. 2010;4(2):143–6.View ArticlePubMedGoogle Scholar
- World Health Organization. Guidelines for establishing DOTS-Plus pilot projects for the management of multidrug-resistant tuberculosis. WHO/CDS/TB/2000.279. Geneva: WHO; 2000.
- Van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis. 2004;8(5):560–7.PubMedGoogle Scholar
- Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. PLoS One. 2009;4(9):e6914. doi:10.1371/journal.pone.0006914.View ArticlePubMedPubMed CentralGoogle Scholar
- Kurbatova EV, Taylor A, Gammino VM, Bayona J, Becerra M, Danilovitz M, et al. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects. Tuberculosis. 2012;92(5):397–403.View ArticlePubMedPubMed CentralGoogle Scholar
- Singla R, Sarin R, Khalid UK, Mathuria K, Singla N, Jaiswal A, et al. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis. 2009;13(8):976–81. Epub 2009/09/03.PubMedGoogle Scholar
- Keshavjee S, Gelmanova IY, Farmer PE, Mishustin SP, Strelis AK, Andreev YG, et al. Treatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study. Lancet. 2008;372(9647):1403–9.View ArticlePubMedGoogle Scholar
- Riekstina V, Leimane V, Holtz TH, Leimans J, Wells CD. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia. Int J Tuberc Lung Dis. 2007;11(5):585–7.PubMedGoogle Scholar
- Cox HS, Kalon S, Allamuratova S, Sizaire V, Tigay ZN, Rüsch-Gerdes S, et al. Multidrug-resistant tuberculosis treatment outcomes in Karakalpakstan, Uzbekistan: treatment complexity and XDR-TB among treatment failures. PLoS One. 2007;2(11):e1126.View ArticlePubMedPubMed CentralGoogle Scholar
- Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, et al. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia. Int J Tuberc Lung Dis. 2006;10(4):402–8.PubMedGoogle Scholar
- Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med. 2006;144(9):650–9.View ArticlePubMedGoogle Scholar
- Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005;365(9456):318–26.View ArticlePubMedGoogle Scholar
- Tupasi TE, Gupta R, Quelapio MI, Orillaza RB, Mira NR, Mangubat NV, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med. 2006;3(9):e352.View ArticlePubMedPubMed CentralGoogle Scholar
- Arora VK, Sarin R, Singla R, Khalid UK, Mathuria K, Singla N, Myneedu VP. DOTS-Plus for Patients with Multidrug-resistant tuberculosis in India: Early Results after three Years. Indian J Chest Dis Allied Sci. 2007;49:75–80.Google Scholar
- Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348(2):119–28.View ArticlePubMedGoogle Scholar
- Jain K, Desai M, Solanki R, Dikshit RK. Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. J Pharmacol Pharmacother. 2014;5:145–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Farley JE, Ram M, Pan W, Waldman S, Cassell GH, et al. Outcomes of Multi-Drug Resistant Tuberculosis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence. PLoS One. 2011;6(7):e20436. doi:10.1371/journal.pone.0020436.View ArticlePubMedPubMed CentralGoogle Scholar